Telix to Acquire ITM for Up to $2.35 Billion to Secure Cancer Isotope Supply
Telix Pharmaceuticals (NASDAQ:TLX) has agreed to acquire Germany’s ITM Isotope Technologies Munich SE in a deal valued up to $2.35 billion, with an upfront payment of $1.65 billion and potential additional payments tied to regulatory approval and sales milestones for ITM's lead drug, ITM-11. The acquisition aims to secure Telix’s supply chain for lutetium-177 isotopes used in its radiopharmaceutical cancer treatments. Currently a key supplier of this isotope, including for Novartis’ Pluvicto, the deal eliminates third-party dependency and reduces scheduling risks. However, it also raises regulatory scrutiny due to ITM’s role as an external supplier to Telix's competitors. The transaction will be financed primarily through 105.8 million new shares of Telix stock, causing immediate dilution for shareholders. The company must secure shareholder approval before the deal closes by year-end. Additionally, ITM-11 has already faced a regulatory rejection from the FDA and requires manufacturing fixes.
Tickers: $TLX
Topics: Cancer treatment Isotope supply chain Pharmaceuticals Radiopharmaceuticals